Stratview Research has published a new report on the IBS-C Drug Market after a thorough analysis of the market. The key sources of information gathered for the report include various industry experts, suppliers, manufacturers, associations along with business distributions. The research report determines unique benefits of the various market size, share and the patent industry.

The objective of the IBS-C Drug Market report is to offer updated information such as the market share, size, trends, emerging markets, earnings, forecasts, and data on leading industry players. This study includes significant and vital information necessary for strategic decision making and have a competitive edge.

In view with the current pandemic analysts at Stratview Research has thoroughly analyzed and presented the following parameters under the detailed Covid – 19 impact analysis in the IBS-C Drug Market.

Detailed Segmentation – According to the report, the IBS-C Drug Market is Segmented, By Product (Linaclotide, Lubiprostone, Stimulant Laxatives, Others), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region – COVID-19 Impact Analysis and Forecast to 2026.

Based on product, the market has been classified into linaclotide, lubiprostone, stimulant laxatives, and others. The linaclotide segment accounted for a substantial market share in 2020. Linaclotide is an oral medication for the treatment of constipation. It is the first in a new class of drugs known as guanylate cyclase-C agonists. It is widely administered for relieving symptoms of irritable bowel syndrome (IBS) with constipation and for treating chronic constipation of unknown causes.

The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to the surge in prevalence of gastrointestinal infection cases, the large presence of advanced healthcare infrastructure, rise in a number of approval for novel IBS-C Drug, as well as presence of major market participants. In addition, the surge in R&D activities in the healthcare sector and enhancement of healthcare infrastructure, and presence of major players operating in the region, which further proliferates the regional growth.

Market Insights – The IBS-C Drug Market is estimated to grow from USD xx million in 2020 to USD xx million by 2026 at a healthy CAGR of 9.2% during the forecast period.

Critical Questions Answered in the Report

  • What are the key trends in the global IBS-C Drug Market?
  • How has the market (and its various sub-segments) grown in the last five years?
  • What would be the growth driver and growth rate in next five years?
  • What is the impact of COVID-19 on the IBS-C Drug Market?
  • What are the key strategies adopted by the major vendors to lead in the IBS-C Drug Market?
  • What is the market share of the key players?

Target Audience

The following is a list of the customers that the IBS-C Drug Market aims to convert the most:

  • Manufacturing Organizations
  • Distributors & Suppliers
  • Potential Investors

Wish to know more about the study? Click here to get a Free Sample:

Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, or to cover analysis on any particular geography or segment, please send your inquiry at [email protected] or +1-313-307-4176.

What we do –

Stratview Research is a growing market research firm. Experts here illustrate innovative, descriptive, and comprehensive insights through market research to satisfy your individual and organizational objectives. We assist the users to make well-informed, profound and favourable decisions to comprehend the advantages of forthcoming trends, developments, assessments, and opportunities through our precise understanding of the market.

Comments to: IBS-C Drug Market Projected to Grow at a Steady Pace During 2021-2026